MedPharm Ltd.

Guildford, United Kingdom

MedPharm Ltd.

Guildford, United Kingdom

Time filter

Source Type

News Article | June 15, 2017
Site: www.prlog.org

Global Topical Drug Delivery Market, By Product Type {Topical (Solid, Liquid, Semi-Solid), Transdermal (Patches, Gels)}; End-User, Distribution Channel, Geography – Trends and Forecast to 2024 -- Topical drug delivery involves the introduction of a medication to the body surface such as skin or mucous membrane or to the circulatory system by periodic transdermal drug delivery for the treatment of diseases. It is considered as key route for local and systemic treatment. Drugs delivered through this route of administration penetrate deeply into the skin and are better absorbed. Topical drugs such as sunscreens and astringents are used for prophylaxis. They are used in the treatment of skin conditions such as bacterial, fungal, and viral infections; inflammation;pruritus; corns; warts; and other dermatologic conditions. Also products such as transdermal patches provide systemic drug delivery non-invasively. Topical drug delivery includes liquid, semi-solid, solid, and transdermal patches and gels.Global topical drug delivery market is expected to reach USD 205.1 billion by 2024 from USD 101.7 billion in 2016, growing at a CAGR of 9.2% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.The global topical drug delivery market is segmented on the basis of product type, indication, distribution channel, end user and geography.·         Topical1.    Solid2.    Liquid3.    Semi-Solid·         Transdermal1.    Patches2.    Gels·         Hospitals·         Clinics·         Home Healthcare·         Diagnostic Centers·         Direct Tenders·         RetailBased on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.·         MedPharm·         Janssen Pharmaceuticals, Inc. (A J&J Company)·         Crescita Therapeutics·         West Pharmaceutical Services·         Biofarmitalia s.r.l·         Pharmatek Laboratories, Inc.·         Stiefel Laboratories, Inc.·         Tapemark·         Acrux Limited·         Nitto Denko Corporation·         Skinvisible Pharmaceuticals, Inc.·         Mylan Pharmaceuticals Inc.·         Pocono Coated Products LLC·         TheraSolve NV.·         Samyang Biopharmaceuticals Corporation·         Lohmann Therapie-Systeme AG·         Prosollus Pharmaceuticals·         Easton Pharmaceuticals Inc.·         Novosis AG·         Endo Pharmaceuticals Inc.·         Transdermal Technologies, Inc.·         Sheffield Pharmaceuticals, Inc.·         SolvayReport Access: http://databridgemarketresearch.com/ reports/global- radiop... Data Bridge Market ResearchAmanora Chambers, Magarpatta Road,Hadapsar, Pune – 411028Tel: +1-888-387-2818Email: Sales@databridgemarketresearch.comVisit Data Bridge Blog@ http://databridgemarketresearch.com/blog/LinkedIn: https://www.linkedin.com/company/data-bridge-market-research%20/Media Contact: MediaRelations@databridgemarketresearch.comInvestors Contact: Investors@databridgemarketresearch.com


— Segmentation: Global Topical Drug Delivery Market, By Product Type (Topical Drug Delivery Formulations (Solid, Liquid, Semi Solid), Transdermal Drug Delivery Devices (Transdermal Patches, Transdermal Gels)), By End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others), By Distribution Channel (Direct Tenders, Retail), By Geography (North America, Europe, Asia-Pacific, Latin America, Rest of the World) Some of the major factors driving the topical drug delivery market are ability to deliver drug at the desired site, inter-and intra-patient variations, without fluctuations in drug levels, an enhanced suitability for self-medication and improved compliance. Also, increasing aging population, growing prevalence of skin related ailments and rising prevalence of chronic diseases, also new and better technologies for topical drug delivery is expected to boost the growth of this market are the major factors driving the growth of the injectable drug delivery market. The prevalence of diseases and conditions such as infections which includes bacterial infection and fungal infections, inflammations, pain management, acne, sun burns, psoriasis, dermatitis, skin allergy, skin cancer, diabetes, and many others has increased considerably over a period of time. With the increasing age, the cases of acute and chronic diseases are rising. Older population is more prone to diseases such as diabetes, allergy, arthritis, infections, and dermatitis. With the rising prevalence of acute and chronic diseases it has become important for the drug and device manufacturers to develop advanced technologies that will provide more effective treatment for the diseases. In the few years, many developments took place for the topical drug delivery due to the rapid absorption of drugs. With the increasing demand for the treatment of diseases using painless and non-invasive method the demand for topical drug delivery is increasing. According to DataBridge Market Research analysts, Japan, Europe and North America are expected to account for around 73% of total global pharmaceutical market, while the rest of the world only own 27% of the market. The major players in the topical drug delivery prescription drugs are • Galderma Pharma, S.A., • Allergen Plc. Kaken Pharmaceuticals, Co., Ltd, • Pfizer, • Bayer AG, • 3M, • Hisamitsu Pharmaceuticals, Co., Inc., • Abbvie, Inc., • Valeant Pharmaceuticals, • Antares Pharma • among others. Some of the other players in the global topical drug delivery market are MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others. 1. INTRODUCTION 1.1. OVERVIEW OF THE GLOBAL TOPICAL DRUG DELIVERY MARKET 1.2. MARKET SEGMENTATION & COVERAGE 2. RESEARCH METHODOLOGY 2.1. KEY TAKEAWAYS 2.2. ARRIVING AT THE GLOBAL TOPICAL DRUG DELIVERY MARKET SIZE 2.4. GLOBAL TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT 2.5. ASSUMPTIONS 3. MARKET LANDSCAPE SUMMARY 4. PREMIUM INSIGHTS 4.1. OVERVIEW 4.2. GLOBAL TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS 4.3. MARKET OVERVIEW 4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES 5. EXECUTIVE SUMMARY 6. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE 6.1. OVERVIEW 6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE 7. TOPICAL DRUG DELIVERY MARKET, BY END-USER 7.1. OVERVIEW 7.2. HOSPITALS 7.3. HOME HEALTHCARE 7.4. CLINICS 7.5. DIAGNOSTIC CENTERS 7.6. OTHERS 8. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 8.1. OVERVIEW 8.2. HOSPITAL PHARMACIES 8.3. PHARMACY STORES 8.4. DIRECT TENDERS 8.5. ONLINE PHARMACY 9. TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY 9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY) 9.1.1. NORTH AMERICA 9.1.1.1. U.S. 9.1.1.2. CANADA 9.1.1.3. MEXICO 9.1.2. EUROPE 9.1.2.1. GERMANY 9.1.2.2. FRANCE 9.1.2.3. U.K. 9.1.2.4. ITALY 9.1.2.5. SPAIN 9.1.2.6. RUSSIA 9.1.2.7. TURKEY 9.1.2.8. BELGIUM 9.1.2.9. NETHERLANDS 9.1.2.10. SWITZERLAND 9.1.2.11. REST OF EUROPE 9.1.3. ASIA-PACIFIC (APAC) 9.1.3.1. JAPAN 9.1.3.2. CHINA 9.1.3.3. SOUTH KOREA 9.1.3.4. INDIA 9.1.3.5. AUSTRALIA 9.1.3.6. SINGAPORE 9.1.3.7. THAILAND 9.1.3.8. MALAYSIA 9.1.3.9. INDONESIA 9.1.3.10. PHILIPPINES 9.1.3.11. REST OF APAC 9.1.4. LATIN AMERICA 9.1.4.1. BRAZIL 9.1.4.2. REST OF LATIN AMERICA 9.1.5. MIDDLE EAST AND AFRICA 9.1.5.1. SOUTH AFRICA 9.1.5.2. REST OF MIDDLE EAST AND AFRICA 9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES 10. TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE 10.1. GLOBAL TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.3. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.6. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS 10.7. MERGERS & ACQUISITIONS 10.8. NEW PRODUCT DEVELOPMENT & APPROVALS 10.10. EXPANSIONS 10.10. REGULATORY CHANGES 10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS 11. TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES 11.1. JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY) 11.2. CRESCITA THERAPEUTICS 11.3. GALDERMA S.A. 11.4. BIOFARMITALIA S.R.L 11.5. PHARMATEK LABORATORIES, INC. 11.6. STIEFEL LABORATORIES, INC. 11.7. TAPEMARK 11.8. NITTO DENKO CORPORATION 11.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 11.9. MYLAN PHARMACEUTICALS INC. 11.9. HISAMITSU PHARMACEUTICAL CO., INC. 11.10. THERASOLVE NV. 11.11. SAMYANG BIOPHARMACEUTICALS CORPORATION 11.12. LOHMANN THERAPIE-SYSTEME AG 11.13. PROSOLLUS PHARMACEUTICALS 11.14. EASTON PHARMACEUTICALS INC. 11.15. ANTARES PHARMA, INC. 11.16. ENDO PHARMACEUTICALS INC. 11.17. TRANSDERMAL TECHNOLOGIES, INC. 11.18. SHEFFIELD PHARMACEUTICALS, INC. 11.19. SOLVAY 11.20. 3M DRUG DELIVERY SYSTEMS Global Trauma Fixation Market by Types (Internal Fixator Devices (Plates, Screws, Rod Wires & Pins, Fusion Nails), External Fixator Devices), By End-User (Hospital, Orthopedic Clinic) By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) – Industry Trends and Forecast to 2024 About Data Bridge Market Research: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. For more information, please visit http://databridgemarketresearch.com/reports/global-topical-drug-delivery-market/


— The "Global Topical Drug Delivery Market" is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Galderma Pharma, S.A., dominated the topical drug delivery market accounting for a highest market share in 2016, followed by Bayer AG, and Valeant Pharmaceuticals. Other players in this market include Allergen Plc. Kaken Pharmaceuticals, Co., Ltd, Pfizer, 3M, Hisamitsu Pharmaceuticals, Co., Inc., Abbvie, Inc., Antares Pharma among others. Some of the other players in the global topical drug delivery market are MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others. Galderma Pharma S.A. was incorporated in 1981, as a joint between Nestle and L'Oreal. In February, 2014 Nestle SA, entered into an agreement to acquire remaining 50% stake in the company, from L'Oreal S.A. After the completion of the acquisition the company will form the foundation of Nestle Skin Health S.A. Galderma Pharma S.A. is headquartered in Lausanne Switzerland. 1. In July 2016, Galderma announces fda approval of full prescription-strength differin gel for over-the-counter acne use. 2. In July 2016, Galderma announces approval of epiduo gel for the treatment of acne in Japan. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science. 1. On July 2015, the U.S. Food and Drug Administration (FDA) approved Finacea Foam, for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Founded in 1994 and headquartered in Quebec, Canada, Valeant Pharmaceuticals International, Inc. is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics. 1. In August 2016, Valeant announced the re-launch of its generic ofloxacin otic solution to treat bacterial ear infections. The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved. Read more about the Global Topical Drug Delivery Market @: http://databridgemarketresearch.com/reports/global-topical-drug-delivery-market/#utm_source=marketersmedia&utm_campaign=Varsha%20Chaudhari Global Tumour Ablation Market, By Type (Tumour Ablation Systems (Radio Frequency Ablation, Microwave Ablation, HIFU, Laser Ablation, Cryoablation), Image Guidance Products, Accessories), By Cancer Type (Liver, Lings, Kidney, Brain, Bone, Pancreas, Breast, Others), By End-User (Hospitals, Oncology Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Trends and Forecast to 2024 Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. For more information, please visit http://databridgemarketresearch.com/reports/global-topical-drug-delivery-market/#utm_source=marketersmedia&utm_campaign=Varsha%20Chaudhari


Wood D.G.,MedPharm Ltd. | Wood D.G.,King's College London | Brown M.B.,MedPharm Ltd. | Brown M.B.,University of Hertfordshire | Jones S.A.,King's College London
European Journal of Pharmaceutics and Biopharmaceutics | Year: 2012

The application of moderate heat is a safe and effective means to increase drug transport across human skin. However, the cascade of events that follows the exposure of a topical skin formulation to a heating source is not well understood. The aim of this study was to elucidate how three potential rate limiting stages in the drug transport process; formulation release, drug partitioning and epidermal diffusion, responded to changes in local temperature using the model drug lidocaine. Release from the formulation measured using regenerated cellulose membrane was shown to be driven by drug diffusion in the vehicle; it responded linearly when the local temperature was changed (21.6 μg/cm2/h for every 1°C rise) and displayed no measurable partitioning of lidocaine into RCM. Once the drug was within the human epidermis, the structural changes of the barrier controlled its transport. The apparent lidocaine diffusion coefficient through silicone membrane increased from 6.52 to 8.43 × 10-4 over the 32-45°C temperature range, but it increased from 7.74 × 10-5 cm2 h -1 to 4.8 × 10-4 cm2 h-1 in the human epidermis. In the absence of large increases in drug partitioning, fluidisation of the lipids in the upper layers of the epidermis at 37-45°C was shown to facilitate lidocaine diffusion which for human skin transport was the rate limiting process. © 2012 Elsevier B.V. All rights reserved.


Zhao Y.,King's College London | Brown M.B.,MedPharm Ltd. | Brown M.B.,University of Hertfordshire | Jones S.A.,King's College London
Nanomedicine: Nanotechnology, Biology, and Medicine | Year: 2010

Nanoparticulate systems have the potential to improve topical drug delivery because of their capacity to enhance drug loading and dissolution, protect chemically unstable therapeutic agents, and improve product aesthetics. However, the commercial use of nanoparticles in topical products is limited because the evidence that they penetrate intact skin is contradictory, and their ability to release active agents in traditional semisolid vehicles is poor. One way to overcome this problem is to formulate nanoparticles in a dynamic delivery system-that is, one that induces a change upon dose actuation so as to promote drug release. Pressurized pharmaceutical foams are one type of dynamic system that can drive a change of state and excipient concentration after dose actuation. This review summarizes the current status of topical products containing nanoparticles, discusses the recent scientific advances in foam production, and investigates the prospect of incorporating nanoparticles into dynamic topical foams. Recent literature suggests that dynamic foams have the potential to break down the nanoparticles loaded within them, improve drug release from nanoparticles, and enhance topical efficacy. Although the published data to support the use of dynamic systems are limited, it is clear that they provide a promising solution to enhance drug release from nanoparticles, and future research work should aim to investigate these systems in more detail. From the Clinical Editor: The use of nanoparticulate systems in topical products is limited as skin penetration and release of active agents remains controversial. Pressurized pharmaceutical foams represent a dynamic system characterized by a change of state and excipient concentration after dose actuation. The review summarizes the current status of topical nanoparticles utilizing this delivery system. © 2010 Elsevier Inc. All rights reserved.


Benaouda F.,King's College London | Brown M.B.,MedPharm Ltd. | Martin G.P.,King's College London | Jones S.A.,King's College London
Pharmaceutical Research | Year: 2012

Purpose: To understand in situ drug thermodynamic activity when embedded in a supramolecular structured hydrophilic matrix that simultaneously self-assembled during drug supersaturation. Methods: A propylene glycol (PG)/water, hydroxypropyl methyl cellulose matrix containing ethanol was used to support diclofenac supersaturation. Phase behaviour, thermodynamics and drug transport were assessed through the determination of evaporation kinetics, supersaturation kinetics and transmembrane penetration. Results: Initial ethanol evaporation from the drug loaded matrix (2.9±0.4 mg.min -1.cm-2) was comparable to that of the pure solvent (ca. 3 mg.min-1.cm-2). When 25% w/w of the total ethanol from the applied phase was lost (ethanol/water/PG molar ratio of 7:5:1.2), an inflection point in the evaporation profile and a sudden decrease in drug solubility demonstrated that a defined supramolecular structure was formed. The 55-fold decrease in drug solubility observed over the subsequent 8 h drove in situ supersaturation, the rate of which was a function of the drug load in the matrix (y=0.0078x, R2<0.99). Conclusion The self-assembling supramolecular matrix prevented drug re-crystallisation for >24 h, but did not hinder mobility and this allowed the thermodynamic activity of the drug to be directly translated into highly efficient transmembrane penetration. © Springer Science+Business Media, LLC 2012.


Grant
Agency: GTR | Branch: BBSRC | Program: | Phase: Training Grant | Award Amount: 99.93K | Year: 2011

Whole body exposure changes in atmospheric pressure are common. For example, passengers on commercial air flights are exposed to a hypobaric pressure of approximately 170 mm Hg for the duration of the flight. Similarly activities such as deep sea diving and hyperbaric medicine, both of which are becoming more popular, can expose the body pressures of up to 6,000 mm Hg. Physiological changes in blood circulation and respiration under hyper and hypo baric pressures have been well documented, but the effects on xenobiotic entry into the body have not been systematically investigated. Whole body exposure to barometric pressure changes would be expected to have very different effects to local pressure changes induced by methods such as suction because the latter generates a pressure differential which could draw molecules across the barrier and has less profound effects on whole body physiology. The comparative effects of these two means of inducing barometric pressure changes to externally facing barriers such as the skin are at present unknown. The aim of this project is to determine the effects of whole body and local barometric pressure changes on membrane physiology and transmembrane chemical penetration. In oder to achieve this aim the project will: - Design and build a series of specialised cells that will allow the assessment of membrane physiology and penetration under both equilibrated and differential hyper and hypo baric conditions in vitro - Determine the effects of locally induced barometric changes upon membrane physiology and permeability using a complimentry range of transport models and analytical techniques - Mathematically model the process of barrier penetration using the in vitro data and design a series of in vivo tests. - Test whole body exposure changes to acute hyperbaric and hypobarric conditions, compare and contrast this data to the in vitro data and adapt the in silico model describing permeation It is anticipated that the data generated from this work can be used to assess both the toxicological exposure risk and potential to improve the delivery of therapeutic agents when applying barometric stress to biological membranes. Work Plan A systems biology approach to the design will be taken. The employment of a hierarchal series of membranes will allow mathematical modelling and descrition of barrier transport in multiple tissue types. Part 1 - In vitro assessment of barometric pressure changes on transport. A specially designed jacket that can independently seal the donor and receiver compartment of a Franz cell will be designed and tested. A series of both porous and non porous synthetic membranes will be employed to investigate the influence of pressure on permeate diffusion and partition. Part 2 - Mathematical modelling. The data sets generated in Part 1 will be fitted to the ideal behaviour expected from non-porous or porous membrane transport processes. A mathematical model to describing transmembrane transport in the absence of barrier changes under different barometric pressures will be developed and this will inform the study design for Part 3. Part 3 - Skin physiology and barrier changes. The cells designed in Part 1 will be used to assess transmembrane penetration through full thickness skin. Pre and post pressure exposure transepidermal water loss, skin lipid packing, water permeability, coenocyte size and skin anatomy will be characterised using analytical techniques and structural changes correlated to barrier properties. The findings will be used to adapt and test the mathematical model generated in Part 2. Part 4 - In vivo assessment. Whole animal protocols developed in previous work (Staff PhD student, 2010) but adapted to specalised hyper and hypobarric chambers will assess animal physiology, skin barrier properties and skin permeability under differential pressure condi


Patent
MEDPHARM Ltd and University of Reading | Date: 2013-11-12

Unnatural, hygroscopic amino acids are useful to enhance the moisture retention and uptake properties of skin. In particular, such amino acids are N-hydroxyserine, N-hydroxyglycine, L-homoserine, alpha-hydroxyglycine, 2-(aminooxy)-2-hydroxyacetic acid, 2-hydroxy-2-(hydroxyamino) acetic acid, 2-(aininooxy)acetic acid, and combinations thereof.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Concept | Award Amount: 100.00K | Year: 2012

Psoriasis is an autoimmune-mediated chronic disease that reportedly affects 2 % of the world’s population. To date it has been difficult to treat with majority of the successful treatments being systemically active such as methotrexate (MTX) and acitretin, administered orally and biologics, administered by injection. All have serious side effects and although topical treatments have been developed to overcome these issues, none are used when the condition passes its early stages. MTX has demonstrated excellent efficacy for psoriasis however oral administration of MTX is associated with side effects such as liver and kidney disease and gastrointestinal irritation. However, currently there are no approved topical formulations that contain MTX mainly because it is believed that therapeutic levels of MTX at the pathological site are hard to achieve with topical administration. Development of a product that could deliver sufficient levels of MTX to the target site would significantly reduce systemic toxicity and increase patient compliance by reducing treatment times associated with current topical medications. A promising novel strategy to enhance skin permeation is the application of superficial heat in conjunction with chemical enhancers e.g. MedTherm. Superficial heat in combination with certain chemical enhancers results in increased drug delivery to the skin without elevated systemic absorption by temporarily increasing barrier fluidity and drug diffusivity making it easier for the MTX to permeate. The applied heat also provides a relief to itching associated with the psoriasis, a benefit not offered by other topical products. As such, the overall objective of this project is to develop a topical MTX treatment for psoriasis using this novel combination of heat generation and chemical enhancers. Inevitably, this will contribute to reducing the financial burden to the NHS, as well as society in the form of “sick days” taken due to the debilitating condition.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: European | Award Amount: 94.79K | Year: 2014

EurostarsCureDFI

Loading MedPharm Ltd. collaborators
Loading MedPharm Ltd. collaborators